Abstract 338P
Background
Nasal type NKTCL refers to upper aerodigestive tract (UAT) involvement while non-nasal type does not involve UAT at initial diagnosis. Since NKTCLs are predominantly nasal type, there remains little knowledge of non-nasal type disease.
Methods
Newly diagnosed advanced-stage non-nasal and nasal type NKTCL patients from two large cancer centers in the past 10-15 years were retrospectively collected.
Results
The study included 56 non-nasal type NKTCL patients with 139 nasal cases as controls. The non-nasal type NKTCLs exhibited higher Ki-67 expression levels compared to nasal cases (P=0.011) with no significant differences in other baseline features. With a median follow-up of 75.03 months, the non-nasal group showed slightly inferior overall survival (OS) compared to the nasal group (median OS [mOS]: 14.57 vs. 21.53 months, P=0.120). ECOG score≥2 (hazard ratio [HR]=2.18, P=0.039) and LDH elevation (HR=2.44, P=0.012) were correlated with worse OS, and the modified nomogram-revised risk index (NRI) and international prognostic index (IPI) functioned effectively for prognostic stratification. Multi- compared to single-modality therapy led to significantly superior progression-free survival (PFS) and OS (median PFS [mPFS]: 11.53 vs. 2.03 months, P=0.001; mOS: 52.80 vs. 7.70 months, P=0.006). Chemoradiotherapy combination significantly improved survival compared to other modalities (mPFS: 14.00 vs. 3.47 months, P=0.050; mOS: 56.40 vs. 9.30 months, P=0.046), and gemcitabine- compared to non-gemcitabine-based regimens showed a trend towards slightly improved outcomes (mPFS: 10.43 vs. 3.40 months, P=0.106; mOS: 25.13 vs. 9.30 months, P=0.125). Table: 338P
Prognostic stratification of advanced-stage non-nasal type ENKTLs
Model | Variable | Risk stratification | Score | Non-nasal type (n=56) (%) | Nasal type (n=139) (%) |
Modified NRI | Age (>60 vs. ≤60 years)ECOG score (≥2 vs. 0-1) Elevated LDH (yes vs. no) | low risk | 0 | 16(28.6) | 46(33.1) |
high risk | 1 | 30(53.6) | 71(51.1) | ||
2 | 5(8.9) | 20(14.4) | |||
3 | 5(8.9) | 2(1.4) | |||
Modified PINK | Age (>60 vs. ≤60 years) Non-nasal type (yes vs. no) | / | 0 | 0 | 121(87.1) |
1 | 45(80.4) | 18(12.9) | |||
2 | 11(19.6) | 0 | |||
Modified IPI | Age (>60 vs. ≤60 years)ECOG score (≥2 vs. 0-1)Elevated LDH (yes vs. no)Extranodal involvement (≥2 vs. 0-1) | low risk | 0 | 2(3.6) | 6(4.3) |
1 | 16(28.6) | 46(33.1) | |||
high risk | 2 | 28(50.0) | 66(47.5) | ||
3 | 5(8.9) | 19(13.7) | |||
4 | 5(8.9) | 2(1.4) |
Conclusions
Advanced-stage non-nasal type NKTCL patients could achieve comparable prognosis with nasal cases after rational comprehensive therapy. Potent therapy is preferred in young patients with previously untreated disease, good performance status, and relatively low tumor burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chinese Geriatric Oncology Society Scientific Research Fund (CGOS-06-2014-1-1-01600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract